6,728 Shares in Astrazeneca Plc $AZN Purchased by Rexford Capital Inc.

Rexford Capital Inc. acquired a new stake in Astrazeneca Plc (NYSE:AZN) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,728 shares of the company’s stock, valued at approximately $1,327,000. Astrazeneca comprises approximately 0.9% of Rexford Capital Inc.’s portfolio, making the stock its 24th largest position.

Several other hedge funds have also recently added to or reduced their stakes in AZN. Triumph Capital Management purchased a new stake in shares of Astrazeneca in the third quarter valued at about $25,000. MV Capital Management Inc. acquired a new stake in shares of Astrazeneca in the fourth quarter valued at approximately $26,000. Bangor Savings Bank increased its stake in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC purchased a new position in shares of Astrazeneca during the 4th quarter worth approximately $30,000. Finally, YANKCOM Partnership acquired a new position in shares of Astrazeneca during the 4th quarter worth approximately $31,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Stock Down 0.7%

AZN stock opened at $189.66 on Wednesday. The company has a 50 day moving average price of $184.15 and a two-hundred day moving average price of $187.47. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock has a market capitalization of $294.14 billion, a P/E ratio of 28.48, a PEG ratio of 1.66 and a beta of 0.25. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. As a group, sell-side analysts expect that Astrazeneca Plc will post 9.39 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on AZN. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Barclays reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings lowered Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.